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Mediation of the effects of living in extremely
poor neighborhoods by health insurance: breast
cancer care and survival in California, 1996 to
2011
Kevin M Gorey1*, Isaac N Luginaah2, Eric J Holowaty3, Guangyong Zou4, Caroline Hamm5
and Madhan K Balagurusamy6
Abstract
Background: We examined the mediating effect of health insurance on poverty-breast cancer care and survival
relationships and the moderating effect of poverty on health insurance-breast cancer care and survival relationships
in California.
Methods: Registry data for 6,300 women with breast cancer diagnosed between 1996 and 2000 and followed until
2011 on stage at diagnosis, surgeries, adjuvant treatments and survival were analyzed. Socioeconomic data were
obtained for residences from the 2000 census to categorize neighborhoods: high poverty (30% or more poor),
middle poverty (5%-29% poor) and low poverty (less than 5% poor). Primary payers or health insurers were
Medicaid, Medicare, private or uninsured.
Results: Evidence of survival mediation was observed for women with node negative breast cancer. The apparent
effect of poverty disappeared in the presence of Medicare or private health insurance. Women who were so
insured were advantaged on 8-year survival compared to the uninsured or those insured by Medicaid (OR = 1.89).
Evidence of payer moderation by poverty was also observed for women with node negative breast cancer. The
survival advantaging effect of Medicare or private insurance was stronger in low poverty (OR = 1.81) than it was in
middle poverty (OR = 1.57) or in high poverty neighborhoods (OR = 1.16). This same pattern of mediated and
moderated effects was also observed for early stage at diagnosis, shorter waits for adjuvant radiation therapy and
for the receipt of sentinel lymph node biopsies. These findings are consistent with the theory that more facilitative
social and economic capital is available in low poverty neighborhoods, where women with breast cancer may be
better able to absorb the indirect and direct, but uncovered, costs of care. As for treatments, main protective effects
as well as moderator effects indicative of protection, particularly in high poverty neighborhoods were observed for
women with private health insurance.
Conclusions: America’s multi-tiered health insurance system mediates the quality of breast cancer care. The system
is inequitable and unjust as it advantages the well insured and the well to do. Recent health care reforms ought to
be enacted in ways that are consistent with their federal legislative intent, that high quality health care be truly
available to all.
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Background
Studies of cancer care and survival in low-income areas
of Canada and the United States have consistently
observed Canadian advantages over the past generation
[1-5]. More inclusive health insurance in Canada has
been advanced as the most plausible explanation. These
studies were ecological with respect to the measurement
of socioeconomic status (SES). They used census tract
data to define low-income neighborhoods, however, their
lowest income areas typically only ranged from 10% to
20% poor. So they had limited power to study cancer care
among “the truly disadvantaged” that live in America’s
poorest neighborhoods where 30% to 40% or more of the
households have incomes below the poverty line [6-8].
Recent analyses have suggested several reasons for the
importance of investigating breast cancer care in such
vulnerable places [2,5]. First, breast cancer is the most
common cancer among American women and its prog-
nosis is typically excellent with early diagnosis and
treatment [9,10]. Second, a direct association between
income and breast cancer survival has been consistently
observed [2,11]. Third, as increasingly effective screens
and treatments have proliferated evidence has mounted
that the best care is more accessible to women of higher
SES [3-5,12-17]. Fourth, being underinsured has also
been associated with less than optimum care [18-24].
These US studies have also for the most part had insuffi-
cient samples and statistical power to study the quality
of breast cancer care among those at greatest risk of not
receiving it; the very poor and the inadequately insured.
Combined effects of being underinsured and living in
extremely poor neighborhoods
International studies have allowed us to develop the the-
ory that SES-cancer care relationships are probably
mediated by health insurance [2,25-27]. It is also prob-
able that within the multi-payer US health care system
the effects of various health insurers interact with other
resources in ways not yet studied. However, thus far this
field has primarily focused on advancing knowledge
about main effects. More complex hypotheses about me-
diation and moderation effects have, for the most part,
not been formally tested [17]. A recent study of ours
may have been the first to test such effects in American
cancer care [27]. We found evidence that having health
insurance significantly mediated or buffered the poverty-
survival relationship for women with colon cancer, but
not for men. We also found that poverty moderated the
health insurance-survival relationship, again only for
women. The advantaging effects of all health insurers,
public and private, were significantly larger for women
in low-poverty neighborhoods. The present study will
examine these relationships among women with breast
cancer.
Health insurance in transaction with social capital
Our SES-health insurance-cancer care mediation theory
aims to model care gaps in America’s most vulnerable
communities. Its foundation is William Julius Wilson’s
work in 1960s Chicago’s high poverty neighborhoods
and Paul Jargowsky and Mary Jo Bane’s research in
America’s extremely poor neighborhoods in the 1970s
and 80s [6-8]. Together they described places of preva-
lent demographic vulnerability that were particularly dis-
tressed for their lack of social and economic capital.
Medicaid and Medicare, the government’s, respective,
mean-tested and entitlement, health insurance programs
were specifically designed to mediate the effects of such
impoverishment. But SES and public and private health
insurance probably interact in important ways across
America’s economic divide. A recent survey demon-
strated how SES and health insurance can interact in the
lives of people with cancer. It surveyed mostly insured
people with colon cancer and found that more than a
third of them suffered one or more significant financial
hardships as a result of their treatment [28]. Moreover,
more than one of every ten of them reported coverage
denials by their insurers with consequent inabilities to
adhere to prescribed treatment regimes. And low-income
households were much more likely to be so impacted.
It seems that the effectiveness of various health insurance
programs may be significantly moderated by other resources.
Those most likely to be disadvantaged are the poor. It is they
who are the least likely to be able to bare the indirect (time
lost from work, child care and travel) and direct, but uncov-
ered costs (deductibles, co-insurances and co-payments) of
contemporary cancer care in America [29].
Hypotheses
The objective of this study was to evaluate the distinct
mediating and moderating effects of SES and health
insurance on cancer care in extremely poor communities
in the US. We hypothesized that the inverse poverty-
breast cancer survival relationship would be significantly,
if not completely, mediated or explained by the intermedi-
ate effect of having health insurance (private, Medicare or
Medicaid). We also hypothesized a health insurance by
poverty interaction, that is, that the direct insurance-
breast cancer survival relationship would be significantly
moderated by poverty (all types of health insurance would
be less effective in high poverty neighborhoods) [30,31].
We then explored similar hypotheses across breast cancer
care from diagnoses to adjuvant or palliative therapies.
Methods
The sampling frame was the California cancer registry
(CCR) which validly monitors the most populous US
state [32-34]. California seems an appropriate place
for this study as its population in high poverty
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neighborhoods nearly doubled between 1990 and 2000
while the nation’s population in high poverty neighbor-
hoods decreased significantly [35,36]. Registry data was
obtained for 6,300 women with invasive breast cancer
diagnosed between 1996 and 2000 [37] and followed until
2011. Cases were randomly selected from three geo-
graphic place strata (2,100 cases each): megalopolises
(greater San Diego, the San Francisco Bay area and greater
Los Angeles), smaller metropolitan areas (Salinas, Mod-
esto, Stockton, Bakersfield and Fresno) and rural places
with population densities less than 400 per km2 [38-40].
This study was powered to detect rate differences of 5%
between 3 geographic place and 3 socioeconomic strata
with 80% power at a 2-tailed significance level of 5%
[41,42].
Variables
Poverty and payers
We first linked breast cancer patients to the US (2000)
census by their residential census tracts [38]. Next, to
model our poverty measure after those that have been
the most validated, we defined the following neighbor-
hoods: high poverty (30% or more of households poor),
middle poverty (5%-29% poor) and low poverty (less
than 5% poor) [2,5-8,43-45]. Socioeconomic distribu-
tions of our sample’s poverty tertiles are displayed in
Table 1. The prevalence of poverty in the typical high
poverty neighborhood was 37%, just about mid-point
between Wilson’s (30%) and Jargowsky and Bane’s (40%)
criterion definitions of high poverty. The typical annual
household income of $23,275 in such high poverty
neighborhoods in 2000 seems a face valid definition of
an extremely poor household. Most of this field’s hereto-
fore low-income or “poor” samples would have fell into
this study’s middle poverty group.
Health insurance status, defined as the primary source
of payment to the hospital or primary payer, was deter-
mined from medical records during the initial course of
treatment. It was categorized as uninsured, Medicaid,
Medicare (with or without any supplementation or any
other non-means-tested governmental payer) or private
insurer (any commercial managed care corporation or
fee-for-service provider). The two key study variables of
neighborhood poverty and primary payer are cross-
tabulated in Table 2. Women with breast cancer living in
high poverty California neighborhoods were one and a
half times as likely to be uninsured, more than twelve
times as likely to be primarily insured by Medicaid, but
only two-thirds as likely to be covered by a private insurer
as were their counterparts in low poverty neighborhoods.
Breast cancer care
Variables from hospital and physicians’ office charts and
clinic reports were coded by the CCR [46,47]. These
were stage of disease at diagnosis (node negative, node
positive or distally metastasized), receipt of initial
surgery, type of surgery (lumpectomy or mastectomy),
receipt of adjuvant radiation therapy, chemotherapy or
hormone therapy, wait times from diagnosis to initial
surgery and from surgery to adjuvant therapies, receipt
of breast reconstruction surgery (post-mastectomy) and
survival time from diagnosis to death or last follow-up
at 10 years. All of these variables had less than 5% miss-
ing data. Tumor size (88.2%), histological grade (85.1%)
and hormone receptor statuses (estrogen and progester-
one receptors, 93.3%) were also coded for the vast
majority of the sample. Various long wait criteria that
may be associated with recurrences, metastases or
shorter survival were explored [3,48-52].
Table 1 Prevalence of poor households in breast cancer
patients’ neighborhoods: California, 2000
Neighborhood
poverty
Prevalence (%) of households
Living in poverty
Range Median Income,a $
Low 0.00–4.99 3.36 74,000
Middle 5.00–29.76 11.40 44,200
High 30.09–100.00 36.84 23,275
Note. Neighborhood income derived from US Census data [38].
a Census tract median annual household income.
Table 2 Primary payers among women with breast cancer
in low, middle and high poverty neighborhoods:
age-adjusted prevalence estimates and standardized
prevalence ratios
Neighborhood poverty
By primary payer Sample Prevalence PR (95% CI)
Low Poverty
Uninsured 183 .086 1.00
Medicaid 25 .012 1.00
Medicare 525 .263 1.00
Private 1,367 .638 1.00
Middle Poverty
Uninsured 226 .108 1.26 (1.04, 1.52)
Medicaid 130 .062 5.17 (3.60, 7.42)
Medicare 577 .275 1.05 (0.94, 1.17)
Private 1,167 .555 0.87 (0.83, 0.91)
High Poverty
Uninsured 276 .133 1.55 (1.30, 1.85)
Medicaid 310 .151 12.58 (9.28, 17.05)
Medicare 672 .307 1.17 (1.06, 1.29)
Private 842 .408 0.64 (0.60, 0.68)
Notes. PR = prevalence ratio, CI = confidence interval. A prevalence ratio of
1.00 was the between-place baseline. Middle and high poverty neighborhoods
were compared to low poverty neighborhoods on payer prevalence estimates.
Bolded PRs were statistically significant at p < .05.
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Descriptive profiles of the breast cancer patients in
our sample are displayed in Table 3. As planned, diverse
geographic places, large urban to rural, and types of
neighborhoods, high poverty to relatively affluent, were
represented. Demographically, our age-diverse sample of
younger working-age women (57.6%) and older women
of retirement age (42.3%) seems consistent with expecta-
tions. More than half of them were primarily covered by
a commercial, private insurer (53.6%). Given our over-
sampling of very poor neighborhoods, the relatively low
representation of the uninsured (10.9%) may seem sur-
prising. Note though that most initial breast cancer care
takes place in hospitals where social workers work to
connect uninsured patients to any additional resources,
typically Medicaid or Medicare, for which they are quali-
fied by virtue of being poor, older or disabled.
Statistical analyses
We used logistic regression models to test hypotheses
about the mediating and moderating effects of poverty
and payers in predicting binary (survived or not) all-
cause breast cancer survival [53-55]. Odds ratios (ORs)
and 95% confidence intervals (CIs) were estimated. Sur-
vival outcomes that were best predicted by main poverty
and payer effects and their interactions were analyzed
and reported: 8-year for node negative, 5-year for node
positive and 3-year for distally metastasized disease
(Hosmer-Lemeshow test [55,56]). ORs estimate the rela-
tive predictive weights of main and interacting effects.
However, under the circumstances of this study, where
both social exposures and key outcomes are common,
ORs probably overestimate rate ratios (RRs) [57]. So we
provided accompanying practical assessments more ger-
mane perhaps to clinical and policy significance. Rates
were directly adjusted for age and other relevant covari-
ates that significantly and substantially confounded
poverty- or payer-breast cancer care relationships, using
this study’s sample as the standard and reported as rates
per 100 cases or percentages. Then we used standardized
RRs for between-group comparisons, with 95% CIs
derived from the Mantel-Haenszel χ2 test [58,59]. Statis-
tical model tests (ORs with 95% CIs) are presented in
Tables 4 ,5, 6, 7 and 8 with accompanying “real world”
practical significance indices (RRs with 95% CIs) reported
as interpretive adjuncts in the text. Because some of our
subsample-based hypotheses could be deemed exploratory
we also reported as approaching significance any finding
that met the more liberal statistical criterion of p < .10.
Results
Interacting effects of poverty and health insurance on
breast cancer survival
Regression models for node negative, node positive and
metastasized breast cancer survival are displayed in
Table 4. Substantial support for both mediation and
moderation hypotheses was observed for node negative
disease. The top left column shows significant main
effects of poverty (OR = 0.54) and payer (OR = 1.57)
when these factors entered regression models alone.
Moving down to the full model, consistent with medi-
ation, in the presence of payer the effect of poverty
disappeared and the effect of adequate payers was
strengthened (OR = 1.89). The 8-year survival rate
among those insured privately or by Medicare (75.5%)
was nine percent greater than that of the uninsured or
those covered by Medicaid (69.0%, RR = 1.09, 95% CI
1.03, 1.15).
The hypothesis that the health insurance-survival rela-
tionship would be moderated by poverty was also sup-
ported for women with node negative disease. The
statistical interaction’s practical effect moderation is
depicted in the bottom of Table 4. Having adequate
health insurance seemed much more effective in low
poverty (OR = 1.81, 95% CI 1.11, 2.95) than in high pov-
erty neighborhoods, where Medicare or private insur-
ance did not seem any more effective than having
Medicaid or being uninsured (OR = 1.16, 95% CI 0.82,
1.62). Consistent with social capital theory, the 8-year
survival rate among women with node negative breast
cancer who lived in low poverty neighborhoods and
were primarily covered by Medicare or private insurers
(79.9%) was 13% greater than the survival rate among,
otherwise similar, women primarily covered by Medicaid
or who were uninsured (70.8%, RR = 1.13, 95% CI 1.02,
1.25). A somewhat smaller payer gradient was observed
in middle poverty neighborhoods (75.5% vs 68.4%, RR =
1.10, 95% CI 1.01, 1.20) and no such gradient was
observed in high poverty neighborhoods.
As for women with node positive and metastasized
breast cancer, only significant main effects were
observed. The practical 5-year survival effect of having
Medicare or private coverage, versus Medicaid or none,
for women with node positive disease was similar to that
observed for women with node negative disease. Their
respective survival rates were 73.6% and 66.2% (RR =
1.11, 95% CI 1.03, 1.19). And having such coverage
seems to have made a very large difference in the lives of
women diagnosed with metastasized disease. Those who
were adequately covered were much more likely to have
survived for 3 years (31.8%) than were the inadequately
covered (18.2%, RR = 1.75, 95% CI 1.11, 2.75).
Interacting effects of poverty and health insurance on
breast cancer diagnoses and treatments
Stage at diagnosis
Mediation and moderation hypothesis support was also
found for early diagnosis of node negative disease. In the
full regression model, the apparent effect of living in
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Table 3 Stratification, age, payer, staging, tumor and care characteristics of breast cancer patients diagnosed between
1996 and 2000 and followed until 2011
Sample % Sample %
Stratification characteristics
Places Poverty prevalence (%) in neighborhoods
Large urban 2,100 33.3 < 5 2,100 33.3
Smaller urban 2,100 33.3 5–29 2,100 33.3
Rural 2,100 33.3 ≥ 30 2,100 33.3
Age and primary payer characteristics
Age at diagnosis, y Primary payers
25–44 904 14.3 Private insurers 3,376 53.6
45–54 1,386 22.0 Medicare 1,777 28.2
55–64 1,344 21.3 Medicaid 465 7.4
65–74 1,375 21.8 Uninsured 685 10.9
≥ 75 1,291 20.5
Staging characteristics at diagnosis
Summary stage Size of tumor, mm
Local-regional < 10 975 17.5
Node negative 4,035 66.2 10–19 2,035 36.6
Node positive 1,774 29.1 20–49 2,035 36.6
Distally metastasized 287 4.7 ≥ 50 512 9.2
Missing data 204 3.2 Missing data 743 11.8
Tumor characteristics
Histological grade Hormone receptor statuses
I, well differentiated 1,134 21.1 Estrogen positive 3,720 63.3
II, moderately 2,211 41.2 Progesterone positive 3,189 54.3
III/IV, poorly 2,019 37.6 Either positive 3,852 65.5
Missing data 936 14.9 Missing data 422 6.7
Cancer care characteristics
Surgery received Wait time from diagnosis to surgery, d
Lumpectomy 3,025 48.4 ≤ 7 2,699 45.8
Mastectomy 2,876 46.0 8–30 2,011 34.1
No surgery 348 5.6 ≥ 31 1,187 20.1
Missing data 51 0.8 Missing data 4 0.1
Received RT 2,843 45.4 Wait time after surgery for RT, d
Missing data 44 0.7 ≤ 60a 1190 42.9
61–90 451 16.3
91–180 687 24.8
≥ 181 446 16.1
Missing data 69 2.4
Received chemotherapy 2,299 37.6 Wait time after surgery for chemotherapy, d
Missing data 185 2.9 ≤ 30b 891 40.7
31–60 839 38.3
61–90 273 12.4
≥ 91 188 8.6
Missing data 108 4.7
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Table 4 Logistic regression main effects and interactions of neighborhood poverty and primary payer by breast cancer
stage at diagnosis on survival
Local-Regional Distally Metastasized
Node negative disease Node positive disease
8 year survival 5 year survival 3 year survival
Predictor Variables Sample OR (95% CI) Sample OR (95% CI) Sample OR (95% CI)
Single predictor models
Neighborhood poverty
< 5% poor 1,435 1.00 561 1.00 55 1.00
5-29% poor 1,353 0.73 (0.61, 0.88) 574 0.70 (0.53, 0.93) 97 0.76 (0.37, 1.59)
≥ 30% poor 1,247 0.54 (0.45, 0.65) 639 0.41 (0.31, 0.53) 135 0.63 (0.31, 1.29)
Primary payer
Uninsured or Medicaid 572 1.00 382 1.00 84 1.00
Medicare or private 3,463 1.57 (1.27, 1.96) 1,392 1.86 (1.44, 2.41) 203 2.51 (1.28, 4.92)
Full models
Neighborhood poverty
< 5% poor 1,435 1.00 561 1.00 55 1.00
5-29% poor 1,353 0.92 (0.67, 1.26) 574 0.72 (0.55, 0.96) 97 0.79 (0.38, 1.68)
≥ 30% poor 1,247 0.84 (0.50, 1.40) 639 0.44 (0.34, 0.58) 135 0.76 (0.36, 1.59)
Primary payer
Uninsured or Medicaid 572 1.00 382 1.00 84 1.00
Medicare or private 3,463 1.89 (1.26, 2.84) 1,392 1.59 (1.22, 2.07) 203 2.40 (1.21, 4.79)
Poverty by payer 4,035 0.79* (0.60, 1.04) 1,774 1.20a (0.85, 1.69) 287 1.17a (0.39, 3.54)
Poverty by payer interaction among women with node negative disease on 8 year survival
> 30% poor 5-29% poor < 5% poor
Sample OR (95% CI) Sample OR (95% CI) Sample OR (95% CI)
Primary payer
Uninsured or Medicaid 277 1.00 186 1.00 109 1.00
Medicare or private 970 1.16 (0.82, 1.62) 1,167 1.57 (1.09, 2.27) 1,326 1.81 (1.11, 2.95)
Notes. OR = odds ratio, CI = confidence interval. All effects were age-adjusted across these categories: 25–44, 45–54, 55–64, 65–74 and 75 or older. After age,
poverty and payer were accounted for, place (large urban, smaller urban or rural) and race/ethnicity (person of color [32.1%] or non-Hispanic white) did not enter
any of the full models. Bolded ORs were statistically significant at p < .05.
a Null interaction was removed from the full model. * p < .10.
Table 3 Stratification, age, payer, staging, tumor and care characteristics of breast cancer patients diagnosed between
1996 and 2000 and followed until 2011 (Continued)
Received HT 2,115 34.7 Wait time after surgery for HT, d
Missing data 205 3.3 ≤ 30c 701 34.7
31–90 667 33.0
91–180 408 20.2
≥ 181 247 12.2
Missing data 92 4.3
Note. RT = radiation therapy, HT = hormone therapy.
a A few (41) of these patients received RT prior to or without surgery.
b One third (32.4%) of these patients received chemotherapy prior to or without surgery.
c One fifth (18.5%) of these patients received HT prior to or without surgery.
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high poverty neighborhoods disappeared, whereas the
effect of payer (OR = 1.73) seemed strengthened and a
poverty by payer interaction that approached statistical
significance was detected (left column of Table 5).
Evidence of this moderation of the effect of payer by
poverty is depicted in the bottom of the table: low poverty
(OR = 1.76) and middle to high poverty neighborhoods
(OR = 1.28). In low poverty neighborhoods, women with
Medicare or private health insurance were nearly 20%
more likely (69.1%) to have been diagnosed with node
negative disease than were the uninsured or those covered
by Medicaid (58.3%, RR = 1.19, 95% CI 1.05, 1.34).
Whereas the effectiveness of such health insurers was
much smaller in middle to high poverty neighborhoods,
where their respective early diagnosis rates were 65.3%
and 61.5% (RR = 1.06, 95% CI 1.00, 1.13). As for tumor
size at diagnosis, only significant main effects of high pov-
erty (OR = 0.63) and payer (OR = 1.23) were observed,
and the practical size of the payer-tumor size relationship
was similar to that of the payer-early stage relationship.
Waits for care
Wait times for initial surgery and adjuvant radiation
therapy of local-regional breast cancers are displayed in
Table 6. Two findings are consistent with mediation and
moderation hypotheses. First, payer clearly mediated the
poverty-wait time relationship among women who
received radiation therapy without chemotherapy as the
apparent effect of poverty disappeared in the presence of
the highly significant effect of payer (OR = 0.55, middle
column of Table 6). In fact, the rate of waiting for more
than three months after surgery for radiation therapy
among those covered by Medicare or private insurers
(13.5%) was less than half that of the uninsured or
Medicaid covered (28.6%, RR = 0.47, 95% CI 0.36, 0.61).
Second, poverty seemed to moderate the payer-wait time
relationship among women who received adjuvant radi-
ation therapy with chemotherapy as there was an effect of
payer that approached statistical significance in middle
and low poverty neighborhoods (OR = 0.70, p < .10), but
not in high poverty neighborhoods (bottom of Table 6).
Table 5 Logistic regression main effects and interactions of neighborhood poverty and primary payer on breast cancer
stage at diagnosis
Node negative disease Tumor < 20 mm
Predictor Variables Sample OR (95% CI) Sample OR (95% CI)
Single predictor models
Neighborhood poverty
< 5% poor 1,833 1.00 1,704 1.00
5-29% poor 1,760 0.94 (0.81, 1.08) 1,639 0.88* (0.75, 1.02)
≥ 30% poor 1,723 0.75 (0.65, 0.88) 1,575 0.61 (0.52, 0.71)
Primary payer
Uninsured or Medicaid 888 1.00 796 1.00
Medicare or private 4,428 1.42 (1.21, 1.65) 4,122 1.37 (1.16, 1.61)
Full models
Neighborhood poverty
< 5% poor 1,833 1.00 1,704 1.00
5-29% poor 1,760 1.27 (0.88, 1.84) 1,639 0.89 (0.76, 1.04)
≥ 30% poor 1,723 1.06 (0.74, 1.52) 1,575 0.63 (0.54, 0.73)
Primary payer
Uninsured or Medicaid 888 1.00 796 1.00
Medicare or private 4,428 1.73 (1.23, 2.44) 4,122 1.23 (1.04, 1.45)
Poverty by payer 5,316 0.72* (0.49, 1.06) 4,918 1.16a (0.93, 1.45)
Poverty by payer interaction on node negative disease at diagnosis
> 5% poor < 5% poor
Predictor Variables Sample OR (95% CI) Sample OR (95% CI)
Primary payer
Uninsured or Medicaid 730 1.00 158 1.00
Medicare or private 2,753 1.28 (1.07, 1.53) 1,675 1.76 (1.25, 2.48)
Notes. OR = odds ratio, CI = confidence interval. All effects were age and grade-adjusted across these categories: 25–44, 45–54, 55–64, 65–74 and 75 or older; and
well, moderately or poorly differentiated. Bolded ORs were statistically significant at p < .05.
a Null interaction was removed from the full model. * p < .10.
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The rate of waiting for more than seven months after sur-
gery for radiation therapy among those covered by Medi-
care or private insurers (16.2%) was approximately 25%
lower than that of the uninsured or Medicaid covered
(21.8%, RR = 0.74, 95% CI 0.52, 1.06, p < .10).
Surgical wait times fit a different pattern. First, there was
a very large effect of poverty (OR = 2.86). Women who
lived in high poverty neighborhoods (12.7%) were two and
a half times as likely to have waited two months or more
for surgery than were women who lived in low poverty
neighborhoods (5.0%, RR = 2.54, 95% CI 2.05, 3.15). Sec-
ond, in the context of such a large effect of poverty, it
seems that having adequate health insurance confers a pro-
tective effect in high and middle poverty (OR = 0.58), but
not in low poverty neighborhoods. In higher poverty
neighborhoods, adequately insured women were about a
third less likely than were uninsured or Medicaid
insured women to have waited two months or more.
Such respective long wait rates were 6.9% and 10.5%
(RR = 0.66, 95% CI 0.52, 0.96). Such long surgical wait
Table 6 Logistic regression main effects and interactions of neighborhood poverty and primary payer on wait times
from diagnosis to surgery and from surgery to radiation therapy among women with local-regional breast cancer
[No chemotherapy] [Had chemotherapy]
Waited > 60 days Waited > 90 days Waited > 210 days
diagnosis to surgery surgery to radiation therapy surgery to radiation therapy
Predictor variables Sample OR (95% CI) Sample OR (95% CI) Sample OR (95% CI)
Single predictor models
Neighborhood poverty
< 5% poor 1,975 1.00 640 1.00 403 1.00
5-29% poor 1,901 1.21 (0.92, 1.59) 507 1.06 (0.71, 1.57) 382 0.84 (0.59, 1.18)
≥ 30% poor 1,841 1.88 (1.46, 2.43) 382 1.50 (1.01, 2.25) 361 0.89 (0.63, 1.26)
Primary payer
Uninsured or Medicaid 934 1.00 224 1.00 252 1.00
Medicare or private 4,783 0.61 (0.48, 0.77) 1,305 0.52 (0.35, 0.77) 894 0.87 (0.62, 1.23)
Full models
Neighborhood poverty
< 5% poor 1,975 1.00 640 1.00 403 1.00
5-29% poor 1,901 1.95* (0.94, 4.03) 507 1.02 (0.69, 1.52) 382 1.92 (1.02, 3.61)
≥ 30% poor 1,841 2.86 (1.40, 5.82) 382 1.37 (0.91, 2.06) 362 1.54 (0.83, 2.84)
Primary payer
Uninsured or Medicaid 934 1.00 224 1.00 252 1.00
Medicare or private 4,783 1.13 (0.56, 2.29) 1,305 0.55 (0.37, 0.82) 894 0.65 (0.42, 1.00)
Poverty by payer 5,717 0.52* (0.25, 1.11) 1,529 1.03a (0.64, 1.67) 1,146 1.96* (0.97, 3.97)
Poverty by payer interaction on surgical wait times of more than 2 months
> 5% poor < 5% poor
Sample OR (95% CI) Sample OR (95% CI)
Primary payer
Uninsured or Medicaid 765 1.00 169 1.00
Medicare or private 2,977 0.58 (0.44, 0.75) 1,806 1.18 (0.58, 2.39)
Poverty by payer interaction among women who received chemotherapy on post-surgical wait times of more than 7
months for RT
> 30% poor < 30% poor
Sample OR (95% CI) Sample OR (95% CI)
Primary payer
Uninsured or Medicaid 121 1.00 131 1.00
Medicare or private 240 0.96 (0.59, 1.57) 654 0.70* (0.47, 1.03)
Notes. OR = odds ratio, CI = confidence interval. All effects were age and stage-adjusted across these categories: 25–44, 45–54, 55–64, 65–74 and 75 or older; and
node positive or node negative breast cancer. Bolded ORs were statistically significant at p < .05.
a Null interaction was removed from the full model. * p < 10.
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rates were identical (5.5%) for both payer groups in low
poverty neighborhoods.
Receipt of adjuvant therapies
The effects of poverty and payer on the receipt of adju-
vant therapies for node negative and node positive breast
cancers are, respectively, displayed in Tables 7 and 8. It
should be noted that nearly all of them received initial
surgery (98.5%) and such receipt was not associated with
poverty or any payers. For women with node negative
disease having private health insurance seemed to make
the biggest difference and for women with node positive
disease having any form of health insurance seemed to
confer substantial access advantages over the uninsured.
For women with node negative disease, in addition to
having large main disadvantageous effects on access to ra-
diation and hormone therapies, poverty seemed to moder-
ate the effect that private insurance had in providing
access to both adjuvant radiation and chemotherapies.
Their poverty by payer interactions were, respectively,
significant or nearly significant. The interactions depicted
in the bottom of the table indicated protective effects
conferred by having private health insurance specific to
higher poverty neighborhoods. In high to middle pov-
erty neighborhoods more than three-quarters of the
women who had received breast conserving surgery and
Table 7 Logistic regression main effects and interactions of neighborhood poverty and primary payer on receipt of
initial and adjuvant therapies among women with node negative breast cancer
Radiation therapya Chemotherapy Hormone therapyb
Predictor variables Sample OR (95% CI) Sample OR (95% CI) Sample OR (95% CI)
Single predictor models
Neighborhood poverty
< 5% poor 877 1.00 1,327 1.00 932 1.00
5-29% poor 762 0.80* (0.63, 1.01) 1,232 1.18 (0.94, 1.46) 756 0.77 (0.63, 0.93)
≥ 30% poor 611 0.63 (0.49, 0.81) 1,113 0.96 (0.76, 1.22) 611 0.70 (0.56, 0.86)
Primary payer
All others 980 1.00 1,627 1.00 1,002 1.00
Private 1,270 1.40 (1.12, 1.75) 2,045 1.00 (0.81, 1.24) 1,297 1.38 (1.14, 1.66)
Full models
Neighborhood poverty
< 5% poor 877 1.00 1,327 1.00 932 1.00
5-29% poor 762 0.62 (0.44, 0.87) 1,232 1.16 (0.93, 1.44) 756 0.78 (0.64, 0.95)
≥ 30% poor 611 0.51 (0.37, 0.72) 1,113 0.77 (0.54, 1.10) 611 0.73 (0.59, 0.90)
Primary payer
All others 980 1.00 1,627 1.00 1,002 1.00
Private 1,270 0.97 (0.68, 1.40) 2,045 0.87 (0.66, 1.13) 1,297 1.32 (1.09, 1.60)
Poverty by payer 2,250 1.61 (1.05, 2.46) 3,672 1.43* (0.93, 2.19) 2,299 0.98c (0.79, 1.21)
Poverty by payer interaction on receipt of adjuvant radiation therapy
> 5% poor < 5% poor
Sample OR (95% CI) Sample OR (95% CI)
Primary payer
All others 651 1.00 329 1.00
Private 722 1.56 (1.19, 2.03) 548 1.06 (0.70, 1.61)
Poverty by payer interaction on receipt of chemotherapy
> 30% poor < 30% poor
Sample OR (95% CI) Sample OR (95% CI)
Primary payer
All others 639 1.00 988 1.00
Private 474 1.39* (0.94, 2.06) 1,571 0.86 (0.65, 1.13)
Notes. OR = odds ratio, CI = confidence interval. All effects were age and tumor size-adjusted across these categories: 25–44, 45–54, 55–64, 65–74 and 75 or older;
and less than 10, 10–19 and 20–50 mm or larger. Bolded ORs were statistically significant at p < .05.
a Among women who received breast conserving surgery. b Among women with hormone receptor positive tumors.
c Null interaction was removed from the full model. * p < .10.
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were privately insured received adjuvant radiation ther-
apy (77.3%), whereas, only about two-thirds of other-
wise similar women who were covered by Medicare,
Medicaid or were uninsured did (67.6%, RR = 1.15,
95% 1.07, 1.23). No such effect was observed in low
poverty neighborhoods. In high poverty neighborhoods
there was an even larger effect of being privately
insured on chemotherapy receipt. Respectively, 24.6%
and 19.6% of privately insured and other insured or un-
insured women received chemotherapy (RR = 1.26, 95%
1.00, 1.58). There was no significant effect of being pri-
vately insured in lower poverty neighborhoods. As for
hormone therapy, only significant main effects of pov-
erty and private insurance were observed. Again, having
private insurance or not made a big difference in access
to hormone therapy (50.7% versus 41.7%, RR = 1.22,
95% CI 1.12, 1.33).
For women with node positive disease having any
form of health insurance seemed to confer substantial
advantages over the uninsured. Poverty again moder-
ated the effects of these payers on access to chemo-
therapy and hormone therapy (middle and right
columns of Table 8). Large care gaps were observed
among the uninsured, particularly among the
Table 8 Logistic regression main effects and interactions of neighborhood poverty and primary payer on receipt of
initial and adjuvant therapies among women with non-distally metastasized, node positive breast cancer
Radiation therapy Chemotherapya Hormone therapyb
Predictor variables Sample OR (95% CI) Sample OR (95% CI) Sample OR (95% CI)
Single predictor models
Neighborhood poverty
< 5% poor 497 1.00 364 1.00 364 1.00
5-29% poor 525 0.82 (0.64, 1.05) 321 1.01 (0.73, 1.40) 333 1.19 (0.88, 1.62)
≥ 30% poor 568 0.75 (0.59, 0.96) 393 0.78 (0.56, 1.07) 335 0.90 (0.66, 1.23)
Primary payer
Uninsured 174 1.00 107 1.00 103 1.00
Any insurance 1,416 0.94 (0.76, 1.16) 931 1.12 (0.72, 1.75) 929 0.98 (0.64, 1.50)
Full models
Neighborhood poverty
< 5% poor 497 1.00 324 1.00 364 1.00
5-29% poor 525 0.82 (0.63, 1.05) 321 1.07 (0.77, 1.49) 333 1.32* (0.96, 1.82)
≥ 30% poor 568 0.73 (0.57, 0.93) 393 0.86 (0.62, 1.21) 335 0.90 (0.66, 1.22)
Primary payer
Uninsured 174 1.00 107 1.00 103 1.00
Any insurance 1,416 0.87 (0.70, 1.09) 931 0.64 (0.32, 1.29) 929 0.68 (0.41, 1.15)
Poverty by payer 1,590 0.73c (0.48, 1.12) 1,038 0.59* (0.34, 1.01) 1,032 0.33 (0.13, 0.82)
Poverty by payer interaction on receipt of chemotherapy
> 5% poor < 5% poor
Sample OR (95% CI) Sample OR (95% CI)
Primary payer
Uninsured 75 1.00 32 1.00
Any insurance 639 1.63* (0.91, 2.90) 292 0.55 (0.25, 1.17)
Poverty by payer interaction on receipt of hormone therapy
> 30% poor 5-29% poor < 5% poor
Sample OR (95% CI) Sample OR (95% CI) Sample OR (95% CI)
Primary payer
Uninsured 36 1.00 32 1.00 35 1.00
Any insurance 299 0.72 (0.34, 1.52) 301 2.16 (1.00, 4.69) 329 0.59 (0.28, 1.26)
Notes. OR = odds ratio, CI = confidence interval. Effects on radiation and hormone therapies were age and tumor size-adjusted and effects on chemotherapy were
adjusted for age and the receipt of radiation therapy across these categories: 25–44, 45–54, 55–64, 65–74 and 75 or older; less than 10, 10–19 and 20–50 mm or
larger; and received radiation therapy or not. Bolded ORs were statistically significant at p < .05.
a Among women who received mastectomies. b Among women with hormone receptor positive tumors.
c Null interaction was removed from the full model. * p < .10.
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uninsured that lived in the poorest neighborhoods.
Such residents of high poverty neighborhoods who
had any health insurance were much more likely to
have received chemotherapy (85.5% vs 65.4%, RR =
1.31, 95% CI 1.16, 1.48). And such insured residents
of middle poverty neighborhoods seemed more likely
to have received hormone therapy (53.3% versus
36.6%, RR = 1.46, 95% CI 0.94, 2.27, p < .10). Not
surprisingly, as it is not typically the first adjuvant
treatment choice for node positive breast cancer, no
significant payer effect was observed for radiation
therapy.
Specialized care among women with non-metastasized
disease
Next, we examined surgical procedures that came into
practice (sentinel lymph node biopsy [SLNB]) or contin-
ued to proliferate during the study period (breast con-
serving surgery [BCS]) or that are not yet prevalently
provided (breast reconstruction surgery [BRS]. There
were similar patterns of Medicaid main effects and pov-
erty by private insurance interactions for BCS and BRS.
Those with Medicaid were less likely to receive BCS
(37.1% vs 50.4%, RR = 0.74, 95% CI 0.65, 0.85) and much
less likely to receive BRS (3.2% vs 13.7%, RR = 0.23, 95%
CI 0.12, 0.46) than other women. And private insurance
facilitated access to both BCS (50.2% vs 41.6%, RR = 1.21,
95% CI 1.07, 1.36) and BRS (12.9% vs 5.9%, RR = 2.19,
95% CI 1.55, 3.09) in high and middle poverty neighbor-
hoods, but not in low poverty ones. Medicare or private
health insurance completely mediated the disadvantaging
effect of poverty on receipt of SLNB. Moreover, such cover-
age seemed to greatly facilitate access in low poverty neigh-
borhoods (14.8% vs 6.6%, RR = 2.24, 95% CI 1.19, 4.20)
more modestly facilitate access in middle poverty neighbor-
hoods (10.8% vs 6.2%, RR = 1.74, 95% CI 1.04, 2.91), but
seemed to have no effect in high poverty neighborhoods
were very few women (6.3%) received such an innovative
procedure.
Explorations of palliative care among women with
metastasized disease
There seemed to be main effects of health insurance,
but not poverty on the receipt of surgery and chemo-
therapy. Those with any insurance were about 50% more
likely than the uninsured to have received surgery
(46.7% vs 31.7%, RR = 1.47, 95% CI 0.94, 2.29, p < .10)
and those with Medicare or private coverage were 25%
more likely to have received chemotherapy than the un-
insured or Medicaid covered (58.8% vs 47.2%, RR = 1.25,
95% CI 0.98, 1.60, p < .10). A protective effect of private
insurance on the receipt of radiation therapy was only
observed in middle poverty neighborhoods. More than
half of such privately insured women received radiation
therapy (52.6%), whereas only about a third of those
covered by other than commercial insurers or who were
uninsured did (35.3%, RR = 1.49, 95% CI 0.95, 2.35,
p < .10). No significant main or interacting effects of
health insurance were observed on hormone therapy.
There was, however, quite a strong effect of poverty.
Women in high poverty neighborhoods were only about
half as likely to receive hormone therapy as were their
counterparts in low poverty neighborhoods (36.4% vs
69.2%, RR = 0.53, 95% CI 0.33, 0.84).
Discussion
We found strong support for our hypothesis that health
insurance mediates the poverty-breast cancer survival
relationship. Evidence of survival mediation was
observed for women with the most common and treat-
able type of breast cancer, node negative. The effect of
poverty disappeared in the presence of Medicare or
private insurance. Women who were so insured were
advantaged on survival compared to the uninsured or
those insured by Medicaid. Evidence of insurance effect
moderation by poverty was also observed for women
with node negative disease. The survival advantaging
effect of Medicare or private insurance was strongest in
low poverty neighborhoods, less strong in moderately
poor neighborhoods and nonexistent in high poverty
neighborhoods. This same pattern of mediated and
moderated effects was also observed for stage at diagno-
sis, waits for adjuvant radiation therapy and for receipt
of sentinel lymph node biopsies. These findings are con-
sistent with the theory that more facilitative social and
economic capital is available in more affluent neighbor-
hoods where women with breast cancer may be better
able to absorb the indirect and direct, but uncovered,
costs of care.
We did not find support for our hypothesis that
Medicaid would also mediate the effect of poverty as we
had for women with colon cancer [27]. However, this
study’s sample of women with breast cancer and the pre-
vious study’s sample of women with colon cancer were
demographically distinct. The women with breast cancer
were much younger. They were twice as likely to be of
pre-retirement age and 35% more likely to be covered by
a commercial insurer. Younger women with breast
cancer, more than half of whom had private health in-
surance, benefited greatly from having it. Whereas, older
women with colon cancer, two-thirds of whom did not
have private insurance, seemed to benefit relatively more
from Medicaid coverage.
Medicare or private insurers were the primary payers
for the care of eight out of every ten women in this
study. It seems that the effectiveness of these, most
prevalent, health insurance programs, public and private,
are significantly impacted by the availability of other
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resources. In more well to do neighborhoods where so-
cial and economic capital abounds most women with
breast cancer seem able to absorb the uncovered costs
of cancer care. But high poverty neighborhoods, with
their relative lack of such capital reserves, seem to
remain places of “true disadvantage” [6], especially for
the women who live there. Not only are they much more
likely to be uninsured or underinsured, but even when
insured such insurance programs seem to be less effect-
ive for them there than they are in less impoverished
neighborhoods.
As for treatments, main and moderator effects indica-
tive of protection, particularly in high poverty neighbor-
hoods were observed for women with private health
insurance. All of the following benefits of having com-
mercial coverage among women living in high poverty
neighborhoods were observed: shorter surgical waits,
better access to BCS as well as to adjuvant radiation,
chemo- and hormone therapies. And for women who
received mastectomies, those with private insurance
were more than twice as likely to have also received
BRS.
These findings may seem counter hypothetical, but an
extension of our health insurance-social capital theory
could explain them. In such high poverty neighbor-
hoods, having private health insurance could itself be
deemed an important form of social capital. Especially in
such vulnerable places, private health insurance seems
to operate to the advantage of its holders. One way that
it may operate is through its probable association with
higher quality primary care. Privately insured women are
more likely to have more established, continuous rela-
tionships with primary care physicians. Such relation-
ships are known to provide myriad benefits: preventive
surveillance, referral to and follow-up of specialist care,
and advocacy and coordination throughout care pro-
cesses [60,61]. Clearly, such could make a very big differ-
ence in the life of a woman with breast cancer, especially
if she otherwise has limited personal and community
resources available to her. This is not to say that high
poverty neighborhoods are devoid of such resources. For
example, evidence has been accumulating about the pos-
sible health benefits of living in certain relatively homo-
geneous communities such as Mexican American
barrios [62,63]. Though such ethnic concentrations tend
to be associated with concentrations of poverty, it seems
that people and institutions in these communities pro-
vide quite a bit of effective social and economic support
to one another. Despite their resiliencies though, gaps in
access to key resources including primary care have been
identified there. So it stands to reason that private insur-
ance and attendant primary care could operate to po-
tentiate the strengths and resiliencies that already exist
in such high poverty neighborhoods.
Payer effect sizes
This study’s payer effect sizes estimated with standar-
dized rate ratios ranged from 1.06 to 2.25. Those most
hypothetically central, the effects of having Medicare or
private insurance on early diagnosis and survival among
women with node negative breast cancer in high poverty
neighborhoods, ranged from 1.10 to 1.19. Though sig-
nificant in a statistical sense, they might be thought
small for clinical practice or policy guidance. We think
such would be an interpretive error for the following
reasons. The attribution of risk at the population level is
a function of three factors of which effect size is only
one. It is also important to consider the size of the
population at risk as well as the prevalence of exposures
to the risk factors being studied. In this instance, the
central exposure or risk factor to be mediated is a social
one, that is, residence in a high poverty neighborhood.
The other social exposure of interest or risk factor is the
risk of being inadequately insured, that is, of being
insured by Medicaid or uninsured. More than forty per-
cent of the non-elderly, non-disabled California popula-
tion or more than 13 million people are so affected. The
national estimate approaches 100 million [64-66]. At the
time of this study approximately 34 million Americans
were poor and nearly 10 million of them lived in high
poverty neighborhoods [35,67]. Regrettably, being unin-
sured, Medicaid insured or poor are not rare “exposures”
in California or America. And nearly a quarter of a mil-
lion American women are newly diagnosed with breast
cancer each year [68]. So a change in relative risk of ten
to twenty percent could affect more than 10 thousand
women with breast cancer in California and nearly 50
thousand women in the United States each year. In
terms of population attributable risk, we would deem
these extraordinarily large effects.
Potential limitations
Our use of ecological poverty measures might suggest
alternative explanations for our results. One may wonder
if the racial/ethnic composition of high poverty neigh-
borhoods, rather than their concentration of the poor,
accounted for the care and survival differences we
observed. We do not think so for the following reasons.
First, numerous recent US studies of breast cancer care
and survival have found that socioeconomic differences
explain most racial-group differences [69-74]. Second,
after we accounted for age, and stage as well as the main
and interacting effects of poverty and health insurance
in these analyses, race/ethnicity was not significantly
associated with survival. And third, our research group
observed that health insurance disparities can explain es-
sentially all of the breast cancer care disparities observed
among our sample’s largest ethnic minority group
(15.7%), Mexican Americans [75,76]. In short, while not
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refuting the importance of race, ethnicity and culture in
cancer care [77-79], our analyses suggest that having
adequate health insurance is probably much more
important.
There has been a large unmet need for research on
the validity of ecological measures of SES often used
in public health research. Wilson and Jargowsky and
others have added much knowledge on high poverty
neighborhood measures [6-8,35,36] and our research
group has done work to advance understandings of
poor neighborhoods, analogous to this study’s middle
poverty neighborhoods [80,81]. They seem prevalently
represented by not only the poor, but the near poor
and working poor as well as lower-middle and middle
class people. This study added further to our know-
ledge about vulnerable neighborhoods. For example,
steep gradients were observed for various types of
health insurance across low (e.g., baseline Medicaid
coverage) to high poverty neighborhoods (prevalence
more than 12-fold greater [82,83]). This new know-
ledge about the validity of ecological poverty mea-
sures may advance our understandings about the
contexts in which very poor Americans live. There-
fore, our findings are probably not prone to ecological
fallacy. They may, in fact, help researchers to better
understand contextual measures of SES and so avoid
individualistic fallacies of inference [84,85].
Another possible limitation of our study was incom-
plete information on outpatient treatments [51,86].
Such data are more difficult for cancer registries to
collect than inpatient data. However, the California
breast cancer registry has been enhanced well beyond
the norm and has been shown to be nearly complete
for chemotherapy data [34,87]. In addition, analyses
of disease stage, hospital-based surgery and survival
were unlikely to have been affected [88], and missing
radiation therapy and chemotherapy data were not
prevalent in our sample. Finally, we focused on over-
all survival, rather than cancer-specific survival. Al-
though vital status and length of overall survival are
highly accurate in cancer registries, the underlying
cause of death probably is not [89-91]. Although
death certificate error was a likely limitation, we did
systematically replicate our central all-cause survival
hypothesis tests with cancer-specific ones. If anything,
our overall survival effects were slight underestimates
of cancer-specific ones [90]. And the underlying cause
of many deaths not coded as cancer mortality can be
directly associated with lack of treatment or with can-
cer treatment complications [92]. For all of these
reasons, we think overall survival a valid and policy-
telling outcome. And such would clearly have had no
impact on other indices of breast cancer care such as
diagnoses and treatments.
Conclusions
America’s multi-tiered health insurance system mediates
the quality of breast cancer care. The system is inequitable
and unjust as it advantages the well insured and the well
to do. Recent health care reforms ought to be enacted
across all 50 states in ways that are consistent with their
federal legislative intent, that high quality health care be
truly available to all.
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